Diabetes mellitus

Co-morbidities | 459

Salgarello M, Adesi LB, Visconti G, Pagliara DM, Mangialardi ML. Considerations for performing immediate breast reconstruction during the COVID-19 pandemic. Breast J. 2020 May 7.

PubMed: https://pubmed.gov/32383321. Full-text: https://doi.org/10.1111/tbj.13876 Sama IE, Ravera A, Santema BT, et al. Circulating plasma concentrations of angiotensin-

angiotensin-aldosterone inhibitors. Eur Heart J. 2020 May 14;41(19):1810-1817. PubMed: https://pubmed.gov/32388565. Full-text: https://doi.org/10.1093/eurheartj/ehaa373 Schiffrin EL, Flack J, Ito S, Muntner P, Webb C. Hypertension and COVID-19. Am J Hypertens. 2020 Apr 6. pii: 5816609. PubMed: https://pubmed.gov/32251498. Full-text: https://doi.org/10.1093/ajh/hpaa057 Sheppard JP, Nicholson B, Lee J, et al. The association between blood pres-sure control and

sion: An observational cohort study. Hypertension. 2020 Dec 16. PubMed: https://pubmed.gov/33325240. Full-text: https://doi.org/10.1161/HYPERTENSIONAHA.120.16472 Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020

Mar 18;24(1):108. PubMed: https://pubmed.gov/32188484. Full-text: https://doi.org/10.1186/s13054-020-2833-7 Solomon MD, McNulty EJ, Rana JS, et al. The Covid-19 Pandemic and the Incidence of Acute

Myocardial Infarction. N Engl J Med. 2020 Aug 13;383(7):691-693. PubMed: https://pubmed.gov/32427432. Full-text: https://doi.org/10.1056/NEJMc2015630 Stefanini GG, Montorfano M, Trabattoni D, et al. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes. Circulation. 2020 Apr 30.

PubMed: https://pubmed.gov/32352306. Full-text: https://doi.org/10.1161/CIRCULATIONAHA.120.047525 Szperka CL, Ailani J, Barmherzig R, et al. Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to Insurers. Headache. 2020 May;60(5):833-842. PubMed: https://pubmed.gov/32227596. Full-text: https://doi.org/10.1111/head.13810 Wang Y, Lu X, Chen H, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with

COVID-19. Am J Respir Crit Care Med. 2020 Apr 8. PubMed: https://pubmed.gov/32267160.

Full-text: https://doi.org/10.1164/rccm.202003-0736LE Zhang XJ, Qin JJ, Cheng X, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020 Aug 4;32(2):176-187.e4.

PubMed: https://pubmed.gov/32592657. Full-text: https://doi.org/10.1016/j.cmet.2020.06.015 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 11.

PubMed: https://pubmed.gov/32171076. Full-text: https://doi.org/10.1016/S01406736(20)30566-3

Diabetes mellitus is a chronic inflammatory condition characterized by several macrovascular and microvascular abnormalities. As with hypertension and CVD, many of the above cited studies have also revealed that diabetic patients were overrepresented among the most severely ill patients with COVID-19 and those succumbing to the disease. Among the 23,698 in-hospital COVID-19related deaths during the first months in the UK, a third occurred in people

460 | CovidReference.com

with diabetes: 7,434 (31.4%) in people with type 2 diabetes, 364 (1.5%) in those with type 1 diabetes (Barron 2020). Current data suggest that diabetes in patients with COVID-19 is associated with a two-fold increase in mortality as well as severity of COVID-19, as compared to non-diabetics. In a meta-analysis of 33 studies and 16.003 patients (Kumar 2020), diabetes was found to be significantly associated with mortality from COVID-19 with a pooled odds ratio of 1.90 (95% CI: 1,37-2,64). Diabetes was also associated with severe COVID-19 and a pooled odds ratio of 2.75 (95% CI: 2,09-3,62). The pooled prevalence of diabetes in patients with COVID-19 was 9,8% (95% CI: 8,7%-10,9%). However, it is too early to say whether diabetes is acting as an independent factor responsible for COVID severity and mortality or if it is just a confounding factor. A large retrospective study on the impact of type 2 diabetes (T2D) carefully analyzed 7337 cases of COVID-19 in Hubei Province, China, among them 952 with pre-existing T2D (Zhu 2020). The authors found that subjects with T2D required more medical interventions and had a significantly higher mortality (7,8% versus 2,7%; adjusted hazard ratio, 1,49) and multiple organ injury than non-diabetic individuals. Of note, well-controlled blood glucose was associated with markedly lower mortality (in-hospital death rate 1,1% versus 11,0%) compared to individuals with poorly controlled blood glucose. Similar results were found in a large UK cohort (Holman 2020). A recent review has made some suggestions on the possible pathophysiological mechanisms of the relationship between diabetes and COVID-19, and its management (Hussain 2020). Rigorous glucose monitoring and careful consideration of drug interactions might attenuate worsening of symptoms and adverse outcomes. In a retrospective cohort study of 1213 hospitalized individuals with COVID-19 and pre-existing T2D, metformin use was significantly associated with a higher incidence of acidosis, particularly in cases with severe COVID-19, but not with 28-day COVID-19-related mortality (Cheng 2020). Some treatment strategies for COVID-19 such as steroids and lopinavir/r bear a risk for hyperglycemia. On the other hand, hydroxychloroquine may improve glycemic control in decompensated, treatment-refractory patients with diabetes (Gerstein 2002, Rekedal 2010). However, it remains unclear which COVID-19 treatment strategy works best and if treatment of diabetic patients has to be different from those without diabetes. It is also unclear whether specific diabetes drugs such as DPP4 inhibitors increase or decrease the susceptibility or severity of SARS-CoV-2 infection. Isolated reports of new-onset diabetes in COVID-19 cases have also led to the hypothesis that SARS-CoV-2 is directly cytotoxic to pancreatic islet β cells.